Scopus BioPharma (SCPS) Competitors $0.0003 0.00 (-70.00%) As of 10/14/2025 02:17 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock SCPS vs. SMFL, VRPX, VAXX, TRVN, ARDS, NAVB, GNCAQ, GNCA, STAB, and EVLOShould you be buying Scopus BioPharma stock or one of its competitors? The main competitors of Scopus BioPharma include Smart for Life (SMFL), Virpax Pharmaceuticals (VRPX), Vaxxinity (VAXX), Trevena (TRVN), Aridis Pharmaceuticals (ARDS), Navidea Biopharmaceuticals (NAVB), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Statera Biopharma (STAB), and Evelo Biosciences (EVLO). These companies are all part of the "pharmaceutical products" industry. Scopus BioPharma vs. Its Competitors Smart for Life Virpax Pharmaceuticals Vaxxinity Trevena Aridis Pharmaceuticals Navidea Biopharmaceuticals Genocea Biosciences Genocea Biosciences Statera Biopharma Evelo Biosciences Scopus BioPharma (NASDAQ:SCPS) and Smart for Life (NASDAQ:SMFL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings. Does the media prefer SCPS or SMFL? In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score. Company Overall Sentiment Scopus BioPharma Neutral Smart for Life Neutral Do insiders and institutionals believe in SCPS or SMFL? 28.4% of Smart for Life shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by insiders. Comparatively, 31.7% of Smart for Life shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is SCPS or SMFL more profitable? Company Net Margins Return on Equity Return on Assets Scopus BioPharmaN/A N/A N/A Smart for Life N/A N/A N/A Which has higher earnings & valuation, SCPS or SMFL? Scopus BioPharma has higher earnings, but lower revenue than Smart for Life. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScopus BioPharmaN/AN/A-$11.61MN/AN/ASmart for Life$11.11M0.00-$22.68MN/AN/A Which has more volatility and risk, SCPS or SMFL? Scopus BioPharma has a beta of -0.18, suggesting that its stock price is 118% less volatile than the S&P 500. Comparatively, Smart for Life has a beta of 16.69, suggesting that its stock price is 1,569% more volatile than the S&P 500. SummarySmart for Life beats Scopus BioPharma on 4 of the 5 factors compared between the two stocks. Get Scopus BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SCPS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SCPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart SCPS vs. The Competition Export to ExcelMetricScopus BioPharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13K$1.06B$6.12B$10.45BDividend YieldN/A4.84%5.73%4.77%P/E RatioN/A1.2585.3327.36Price / SalesN/A31.47601.99136.95Price / CashN/A17.6437.4661.86Price / BookN/A7.6612.566.81Net Income-$11.61M-$7.71M$3.32B$276.80M7 Day PerformanceN/A-0.76%0.59%0.42%1 Month PerformanceN/A24.34%10.52%7.86%1 Year PerformanceN/A-12.21%75.05%41.24% Scopus BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCPSScopus BioPharmaN/A$0.00-70.0%N/A+0.0%$13KN/A0.009SMFLSmart for LifeN/A$0.00flatN/A-92.3%$19K$11.11M0.00110Gap DownVRPXVirpax Pharmaceuticals0.0784 of 5 stars$0.01-47.6%N/A-99.9%$14KN/A0.007Gap UpVAXXVaxxinityN/A$0.00flatN/A-97.5%$13KN/A0.0090Gap DownTRVNTrevena1.6737 of 5 stars$0.01flat$5.00+41,566.7%-99.4%$12K$443K0.0040ARDSAridis PharmaceuticalsN/A$0.00flatN/AN/A$11KN/A0.0030Gap UpNAVBNavidea BiopharmaceuticalsN/AN/AN/AN/A$10K$8.13K0.0010High Trading VolumeGNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070STABStatera BiopharmaN/A$0.00flatN/A-50.0%$5KN/A0.0020High Trading VolumeEVLOEvelo BiosciencesN/A$0.00flatN/A-33.3%$4KN/A0.00120News CoverageOptions Volume Related Companies and Tools Related Companies Smart for Life Competitors Virpax Pharmaceuticals Competitors Vaxxinity Competitors Trevena Competitors Aridis Pharmaceuticals Competitors Navidea Biopharmaceuticals Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Statera Biopharma Competitors Evelo Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCPS) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scopus BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scopus BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
